Angiogenesis serum protein quantification for prostate pathology

Current Urology

Volumn 2, Issue 4, 2008, Pages 181-187

  Balacescu, Ovidiu ^a,c   Neagoe, Ioana ^b   Balacescu, Loredana ^a   Crisan, Nicolae ^b   Feciche, Bogdan ^b   Tudoran, Oana ^a   Coman, Ioan ^b   Irimie, Alexandru ^b  

^a Cancer Institute Ion Chiricuta Cluj Napoca   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Cancer Institute   (Romania)

Author keywords

Angiogenesis; FAST Quant ; Prostate; Serum biomarkers

Indexed keywords

ANGIOGENIC PROTEIN; ANGIOGENIN; ANGIOPOIETIN 2; BASIC FIBROBLAST GROWTH FACTOR; BIOLOGICAL MARKER; INTERCELLULAR ADHESION MOLECULE 1; KERATINOCYTE GROWTH FACTOR; PLASMA PROTEIN; PLATELET DERIVED GROWTH FACTOR BB; PROSTATE SPECIFIC ANTIGEN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLOOD LEVEL; CANCER DIAGNOSIS; CELL ADHESION; CHRONIC PROSTATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; FIBROBLAST; HUMAN; HUMAN TISSUE; MALE; NORMAL DISTRIBUTION; PATHOLOGY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 77953422243     PISSN: 16617649     EISSN: 16617657     Source Type: Journal    
DOI: 10.1159/000189664     Document Type: Article

References (35)

1. Hrouda D, Nicol DL, Gardiner RA: The role of angiogenesis in prostate development and the pathogenesis of prostate cancer. Urol Res 2003;30:347-355.
2. Fransworth WE: Prostate stroma: physiol-ogy. Prostate 1999;38:60-72.
3. American Cancer Society: Cancer: Facts and Figures 2008, pl7.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
5. International Agency for Research on Can-cer, www.iarc.fr/en.
6. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomi-cal radical retropubic prostatectomy: results at 10 years. J Urol 1994;152:1831-1836.
7. Zincke H, Oesterling JE, Blute ML, Bergs-tralh EJ, Myers RP, Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
8. Epstein JI, Carmichael MJ, Pizov G, Walsh PC: Influence of capsular penetration on pro-gression following radical prostatectomy: a study of 196 cases with long term follow-up. J Urol 1993;150:135-141.
9. Haukaas SA, Halvorsen OJ, Daehlin L, Host-mark J, Akslen LA: Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical ret-ropubic prostatectomy for localized prostate cancer? BJU Int 2006;97:51-55.
10. Reynolds MA, Kastury K, Groskopf J, Schalken JA, Rittenhouse H: Molecular markers for prostate cancer. Cancer Lett 2007;249:5-13.
11. Stanley TA: Preoperative serum prostate-specific antigen (PSA) below 10 microg/1 predicts neither the presence of prostate can-cer nor the rate of postoperative PSA failure. Clin Chem 2001 ;47:631-634.
12. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA Jr: Operating characteristics of prostate-specific antigen in men with an ini-tial PSA level of 3.0 ng/ml or lower. JAMA 2005;294:66-70.
13. Shih SC, Robinson GS, Perruzzi CA, Calvo A, Desai K, Green JE, Ali IU, Smith LE, Sen-ger DR: Molecular profiling of angiogenesis markers. Am J Pathol 2002;161:35-H.
14. Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP: Thrombospondin-1, vascular endothelial growth factor and fi-broblast growth factor-2 are key functional regulators of angiogenesis in the prostate. Prostate 2001;49:293-305.
15. Ferrer FA, Miller LJ, Andrawis RI, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL: Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology 1998;51:161-167.
16. Lutsenko SV, Kiselev SM, Severin SE: Mo-lecular mechanisms of tumor angiogenesis. Biochemistry (Mosc) 2003;68:286-300.
17. Bussolati B, Deambrosis I, Russo S, Deregi-bus MC, Camussi G: Altered angiogenesis and survival in human tumor-derived endo-thelial cells. FASEB J 2003;17:1159-1161.
18. Fedida S, Fishman D, Suzlovich Z, Argov S, Friger M, Oren L, Segal S, Sion-Vardy N: Impaired access of lymphocytes to neoplastic prostate tissue is associated with neoangio-genesis in the tumor site. Br J Cancer 2007; 96:980-985.
19. Stillman B, Parker B, Tonkinson J, Harvey M: Applying multiplexed microspot immu-noassays. Genetic Engineering News 2004; 24:6.
20. Mehta PB, Robson CN, Neal DE, Leung HY: Serum keratinocyte growth factor measure-ment in patients with prostate cancer. J Urol 2000;164:2151-2155.
21. Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, Lin YC: Effect of kera-tinocyte growth factor on cell viability in pri-mary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol 2006;100: 24-33.
22. Lind AJ, Wikström P, Granfors T, Egevad L, Stattin P, Bergh A: Angiopoietin 2 expres-sion is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate 2005;62:394-399.
23. Huss WJ, Hanrahan CF, Barrios RJ, Simons JW, Greenberg NM: Angiogenesis and pros-tate cancer: identification of a molecular pro-gression switch. Cancer Res 2001; 15:2736-2743.
24. Murdoch C, Tazzyman S, Webster S, Lewis CE: Expression of Tie-2 by human mono-cytes and their responses to angiopoietin-2. J Immunol 2007;178:7405-11.
25. Caine GJ, Blann AD, Stonelake PS, Ryan P, Lip GY: Plasma angiopoietin-1, angiopoi-etin-2 and Tie-2 in breast and prostate can-cer: a comparison with VEGF and Flt-1. Eur J Clin Invest 2003;33:883-890.
26. Caine GJ, Ryan P, Lip GY, Blann AD: Sig-nificant decrease in angiopoietin-1 and angio-poietin-2 after radical prostatectomy in pros-tate cancer patients. Cancer Lett 2007;251: 296-301.
27. Jiang Y, Goldberg ID, Shi YE: Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 2002;21:2245-2252.
28. Brehmer B, Biesterfeld S, Jakse G: Expres-sion of matrix metalloproteinases (MMP-2 and -9) and their inhibitors (TIMP-1 and -2) in prostate cancer tissue. Prostate Cancer Prostatic Dis 2003;6:217-222.
29. Liu AY, Zhang H, Sorensen CM, Diamond DL: Analysis of prostate cancer by pro-teomics using tissue specimens. J Urol 2005; 173:73-78.
30. Lein M, Nowak L, Jung K, Koenig F, Schnorr D, Loening SA: Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma. UrologeA 1998;37:377-381.
31. Leitzel K, Kantoff P, Oh WK, Ditt J, Hamer P, Pierce K, Brown-Shinier S, Carney W, AH SM, Lipton A: Elevated TIMP-1 levels in prostate cancer cell line conditioned me-dium and hormone-refractory prostate cancer patient plasma (abstract No.96). The Prostate Cancer Symposium ASCO 2007.
32. Anand-Apte B, Pepper MS, Voest E, Monte-sano R, Olsen B, Murphy G, Apte SS, Zetter B: Inhibition of angiogenesis by tissue inhibi-tor of metalloproteinase-3. Invest Ophthal-mol Vis Sci 1997;38:817-823.
33. Koike T, Vernon RB, Gooden MD, Sadoun E, Reed MJ: Inhibited angiogenesis in aging: a role for TIMP-2. J Gerontol A Biol Sci Med Sci 2003;58:B798-B805.
34. Robinet A, Faliem A, Cauchard JH, Huet E, Vincent L, Lorimier S, Antonicelli F, Soria C, Crepin M, Hornebeck W, Bellon G: Elas-tin-derived peptides enhance angiogenesis by promoting endothelial cell migration and tubulogenesis through upregulation of MT1-MMP. J Cell Sci 2005;118:343-356.
35. Kim HE, Han SJ, Kasza T, Han R, Choi HS, Palmer KC, Kim HR: Platelet-derived growth factor (PDGF)- signaling mediates ra-diation-induced apoptosis in human prostate cancer cells with loss of p53 function. Int J Radiat Oncol Biol Phys 1997;39:731-736.